Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 107 clinical trials
Featured trial
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.

  • 6 views
  • 19 Sep, 2022
  • 153 locations
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

  • 13 views
  • 20 Sep, 2022
  • 129 locations
Featured trial
BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery

BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery

  • 92 views
  • 25 Mar, 2021
  • 1 location
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia

from taking TAK-079 at three different dose levels. Another aim is to learn if TAK-079 can increase the platelet count in people with ITP. In addition to receiving stable background therapy for

  • 3 views
  • 19 Sep, 2022
  • 8 locations
Niraparib Combined With Radiotherapy in rGBM

platelet count 150,000/L) or 200mg/day (body weight <77Kg or baseline platelet count <150,000/L), combined with radiotherapy (total dose 55Gy), follow-up Time 1 year. Until the patient has disease

  • 1 views
  • 02 Feb, 2021
  • 1 location
Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)

The purpose of this study is to determine if using avatrombopag in patients with thrombocytopenia due to temozolomide treatment can safely improve a patient's platelet count and allow the

avatrombopag
platelet count
small molecule
  • 0 views
  • 30 Jun, 2022
  • 1 location
Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP

Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with low platelet count. As the first choice of the second-line treatment of ITP, thrombopoietin receptor agonist (TPO-RA

platelet count
eltrombopag
  • 1 views
  • 19 Jun, 2021
  • 1 location
Open, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of Bioven, Manufactured by Biopharma Plasma LLC, in Adult Patients With Chronic Primary Immune Thrombocytopenia (ITP)

The study will involve patients with chronic immune thrombocytopenia. This disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other

  • 0 views
  • 20 Aug, 2022
  • 4 locations
NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK)

predictive factors leading to hematologic toxicity were a weight <77kg and an initial platelet count <175 G/L. However, it seems more complex as 50% of patients with an initial weight between 58 and

  • 0 views
  • 05 May, 2022
Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (MP-PDAC-01)

ULN absolute neutrophil count (ANC) ≥ 1,500 cells/µL platelet count ≥ 100,000/µL hemoglobin ≥ 9.0 g/dL Subjects who have at least a

metastatic pancreatic ductal adenocarcinoma
adenocarcinoma
biliary stents
leucovorin
platelet count
  • 1 views
  • 29 Jun, 2022
  • 1 location